CanSino Biologics Inc. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 629.79 million compared to CNY 2,061.46 million a year ago. Net income was CNY 12.24 million compared to CNY 937.13 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.36 HKD | +1.66% | +3.61% | -22.04% |
Apr. 22 | Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine | MT |
Apr. 22 | Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.04% | 1.06B | |
-2.86% | 87.31B | |
+3.95% | 40.86B | |
-21.94% | 29.36B | |
+56.65% | 24.49B | |
-5.41% | 17.31B | |
-44.23% | 11.26B | |
-17.60% | 11.62B | |
-13.96% | 11.31B | |
+5.99% | 8.31B |
- Stock Market
- Equities
- 6185 Stock
- News CanSino Biologics Inc.
- CanSino Biologics Inc. Reports Earnings Results for the Half Year Ended June 30, 2022